Probiotics in the Animal Feed Market: Competition and Growth Outlook to 2030 Featuring ADM, DSM-Firmenich, Evonik Industries, International Flavors & Fragrances, Land O'Lakes & More
Global Probiotics in Animal Feed Market
Dublin, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The "Probiotics in Animal Feed Market by Source (Bacteria, Yeast & Fungi), Livestock (Poultry, Swine, Ruminants, Aquaculture, Pet, and Other Livestock), Form (Liquid, Dry), Strain Specificity, Function, Distribution Channel, and Region - Global Forecast to 2030" has been added to ResearchAndMarkets.com's offering.
The global market for probiotics in animal feed is projected to grow from USD 5.40 billion in 2025 to USD 8.27 billion by 2030, at a CAGR of 8.9%. This growth is driven by increasing demand for high-quality animal protein, regulatory changes regarding antibiotic use, and heightened awareness of gut health's impact on animal performance.Adoption is notably strong in the poultry and swine sectors, in line with consumer demand for antibiotic-free and responsibly produced animal products.
The poultry segment is anticipated to be the fastest-growing in the probiotics in animal feed market. This growth is attributed to the rising global demand for poultry products and concerns over antibiotic resistance. Probiotics support gut health, immunity, and feed efficiency in poultry, facilitated by a shift toward sustainable, antibiotic-free farming. Advances in strain-specific formulations and notable growth in regions like Asia Pacific further propel this segment's rapid expansion.
The yeast & fungi segment is expected to see rapid growth in the probiotics in animal feed market. Driven by demand for natural, sustainable feed additives, yeast, particularly, is gaining popularity as a safe antibiotic alternative. It enhances gut health and nutrient absorption while reducing disease risk. The movement towards organic and antibiotic-free products accelerates adoption, with biotechnological advances offering more targeted and efficient strains.
Asia-Pacific is forecasted to be the fastest-growing region in the probiotics in animal feed market. Growth in this region is bolstered by rapid urbanization, rising incomes, and expanding livestock industries. Developing countries are driving growth with increased animal protein demand and government support for sustainable practices. The region's agricultural sector, particularly poultry, is adopting probiotics to improve animal health and productivity, contributing to overall market expansion.
Research Scope: The report covers a range of sectors including source (bacteria, yeast & fungi), livestock (poultry, swine, ruminants, aquaculture, pets, others), form (liquid, dry), and more. Detailed analyses of drivers, restraints, challenges, and opportunities impacting market growth are covered alongside in-depth evaluations of key industry players and strategic insights into the competitive landscape.
Reasons to buy this report: This report provides market leaders and new entrants with revenue approximations and insights into competitive landscapes, aiding in better business positioning and strategic planning. It also offers a market pulse, helping stakeholders identify key growth drivers, restraints, challenges, and opportunities.
Report Insights:
Analysis of key drivers, such as the demand for antibiotic alternatives, and restraints like high probiotic costs.
Details on service launches and R&D in the probiotics sector.
Comprehensive market development information across various regions.
Diversification opportunities, including new services, geographies, and recent developments.
Competitive assessments of market players, including strategies, offerings, and product comparisons.
Key Attributes
Report Attribute
Details
No. of Pages
253
Forecast Period
2025-2030
Estimated Market Value (USD) in 2025
$5.4 Billion
Forecasted Market Value (USD) by 2030
$8.27 Billion
Compound Annual Growth Rate
8.9%
Regions Covered
Global
Market Dynamics
Drivers
Ban on AGPs and Health Campaigns to Promote Probiotics as Feed Alternatives
Increased Demand for Animal Protein and Other Livestock Products
Better Gut Health and Efficiency Through Probiotics
Challenges
High Costs of R&D into New Probiotic Strains
Competition from Enzymes and Prebiotics
Opportunities
Development of Species-Specific and Next-Gen Strains
Innovations and Technological Advancements in Feed Industry
Integration with Precision Livestock Farming
Case Studies
Case Study: AI-Developed Probiotics Drive Gut Health, Productivity & Sustainability in Livestock
Companies Profiled
ADM
DSM-Firmenich
Evonik Industries AG
International Flavors & Fragrances Inc.
Land O'lakes, Inc.
Novonesis Group
Kemin Industries, Inc.
Phibro Animal Health Corporation
Church & Dwight Co., Inc
Virbac
Lesaffre
Alltech
Lallemand Inc.
Sanzyme Biologics
Orffa
Zeigler Feeds
Unique Biotech Limited
Provita Animal Health
International Animal Health Products
Advanced Aqua Biotechnologies
Canbiocin Inc.
Indogulf Company
Pellucid Lifesciences Pvt. Ltd.
Animalbiome
Native Microbials
For more information about this report visit https://www.researchandmarkets.com/r/5879ed
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Global Probiotics in Animal Feed Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
22 minutes ago
- Forbes
Why Is The Stock Market Down Today? How Beginners Can Turn Red Days Into Gains
Editorial Note: We earn a commission from partner links on Forbes Advisor. Commissions do not affect our editors' opinions or evaluations. With inflation eating into your savings, relying solely on your nine-to-five paycheck might not be enough. This is where investing comes in. The stock market is in the red again, with major indexes wobbling on renewed concerns about economic growth and interest rate policy. For many long-term investors, days like this feel unsettling. But for beginners just starting out, the question is different: Is a market dip the right moment to get in? The short answer: It can be, if you approach it with the right mindset and tools. When markets fall, many people instinctively want to run. Losses dominate headlines, and even seasoned investors feel anxious watching red tickers scroll across the screen. But history suggests that downturns can present opportunities to those willing to buy and hold. When the market takes a hit, the price of stocks, ETFs and index funds often drop too, creating a chance for new investors to get in at a discount. ETFs are collections of stocks, bonds and other securities that trade like a single asset, and index funds track major benchmarks like the S&P 500. Buying during a dip can mean more shares for your money—much like grabbing a favorite item on sale—and could pay off over the long run. The key is your time spent in the market. If you invest money you won't need for at least five to 10 years, a temporary downturn is unlikely to derail your long-term gains. But if you need quick returns, short-term volatility can sting. If you're nervous about putting a lump sum into the market during a slide, there's a well-tested strategy: dollar-cost averaging. That means investing a set amount of money consistently, regardless of market conditions. Over time, this approach helps smooth out the impacts of market swings. When prices are high, your set investment buys fewer shares. When prices are low, you get more for the same dollar amount, resulting in less pressure to 'time' the market perfectly. If you're new to investing, stocks, ETFs and mutual funds can feel confusing. Online brokers make the process easier—they give you access to the market and tools to help you learn as you go. With an online broker, you can buy and sell investments from your phone or computer without needing to meet a financial advisor in person. Many platforms also offer helpful guides, videos and tutorials, so you can learn the ropes while you start investing. Here are some noteworthy options if you're searching for an online broker for beginners. Before you jump in, a few fundamentals matter more than today's market headlines: Build your emergency fund first. Aim to keep three to six months' worth of expenses in a savings account before committing extra cash to stocks. That way, you won't need to sell investments in a downturn to cover bills. Aim to keep three to six months' worth of expenses in a savings account before committing extra cash to stocks. That way, you won't need to sell investments in a downturn to cover bills. Focus on diversification. Rather than betting on one or two companies, reduce your risk by spreading your money across index funds or ETFs that track the broader market. Rather than betting on one or two companies, reduce your risk by spreading your money across index funds or ETFs that track the broader market. Invest, don't trade. New investors sometimes confuse investing with short-term trading. Long-term wealth is built through patience, not daily buying and selling. New investors sometimes confuse investing with short-term trading. Long-term wealth is built through patience, not daily buying and selling. Use tax-advantaged accounts. Accounts like IRAs or 401(k)s can help maximize your returns through tax breaks. It's impossible to know for certain whether today's drop is the beginning of a larger downturn or just a temporary dip. But history shows markets have consistently trended upward over long horizons. The S&P 500, for instance, has weathered wars, recessions, inflation spikes and tech busts—yet long-term investors who stayed the course were rewarded. That's why successful beginners focus less on the question 'Is now the bottom?' and more about 'How consistently can I invest over time?' A market downturn can feel intimidating, but it also gives new investors a chance to buy in at lower prices. By focusing on diversification, using dollar-cost averaging and choosing the right online broker, beginners can turn today's red screens into tomorrow's growth. Don't try to outguess the market. Instead, play the long game—because in investing, time in the market almost always beats timing the market.
Bloomberg
25 minutes ago
- Bloomberg
Big Take: The Ballooning Cost of a CEO's Exit
From Starbucks and Intel to Petco and Astronomer: Top CEOs are getting replaced at record rates. And the costs of these ousters can spiral quickly, dinging a company's stock price and costing us all in surprising ways in the process. On today's Big Take podcast, Bloomberg's management and work reporter Matthew Boyle joins host Sarah Holder to dig into the often murky, always steep cost of a CEO ouster.
Yahoo
31 minutes ago
- Yahoo
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M-mutation with progressive disease following prior therapy.1 This indication was approved based on five open-label, non-randomized clinical trials conducted in the U.S. (ONC006 [NCT02525692], ONC013 [NCT03295396], ONC014 [NCT03416530], ONC016 [NCT05392374], and ONC018 [NCT03134131]).1 'Onco360 is grateful for the opportunity to add Modeyso™ to our expansive portfolio of cancer and rare disease therapies as the first and only FDA-approved treatment for pediatric and adult patients with diffuse midline glioma,' said Benito Fernandez. 'We are proud and humbled to be part of this innovative treatment in support of patients, caregivers and families impacted by this devastating disease.' Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.1 The efficacy of Modeyso was evaluated in an integrated efficacy population of 50 adult and pediatric patients with recurrent H3 K27M-mutant diffuse midline glioma enrolled across five open-label, non-randomized clinical trials.1 The primary outcome was overall response rate (ORR) of 22% (95% CI: 12,36). The trial also demonstrated a duration of response of 10.3 months (95% CI: 7.3, 15.2) with 73% maintaining their response for at least six months and 27% for at least 12 months.1 Dordaviprone demonstrated manageable safety and tolerability adverse events. The most common adverse reactions (≥20 %; all causality) experienced with dordaviprone were fatigue, headache, nausea, vomiting, and musculoskeletal pain.1 Please see the full Prescribing Information for Modeyso. About Onco360 Oncology Pharmacy:Onco360 is the nation's largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Media Contact: Benito Fernandez, Chief Commercial References:1Modeyso™ (Dordaviprone) [Package Insert]. Palo Alto, CA. Jazz Pharmaceuticals. in to access your portfolio
